Brokerages expect that BioXcel Therapeutics Inc (NASDAQ:BTAI) will report earnings of ($0.58) per share for the current quarter, according to Zacks. Zero analysts have provided estimates for BioXcel Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.60) and the highest estimate coming in at ($0.56). BioXcel Therapeutics reported earnings per share of ($0.31) during the same quarter last year, which would suggest a negative year over year growth rate of 87.1%. The firm is scheduled to announce its next earnings results on Friday, November 8th.
According to Zacks, analysts expect that BioXcel Therapeutics will report full-year earnings of ($2.15) per share for the current fiscal year, with EPS estimates ranging from ($2.20) to ($2.10). For the next year, analysts expect that the business will post earnings of ($2.25) per share, with EPS estimates ranging from ($2.82) to ($1.68). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that follow BioXcel Therapeutics.
BioXcel Therapeutics (NASDAQ:BTAI) last announced its earnings results on Tuesday, August 6th. The company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.02).
In other news, insider Frank Yocca purchased 6,547 shares of the company’s stock in a transaction dated Tuesday, August 13th. The shares were acquired at an average cost of $8.67 per share, for a total transaction of $56,762.49. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Peter Mueller purchased 8,446 shares of the company’s stock in a transaction dated Thursday, August 22nd. The shares were purchased at an average price of $8.74 per share, for a total transaction of $73,818.04. The disclosure for this purchase can be found here. Insiders bought 18,976 shares of company stock valued at $165,104 over the last ninety days. Corporate insiders own 64.80% of the company’s stock.
Several institutional investors have recently modified their holdings of BTAI. Artemis Investment Management LLP increased its stake in shares of BioXcel Therapeutics by 1.0% during the second quarter. Artemis Investment Management LLP now owns 979,015 shares of the company’s stock worth $10,644,000 after acquiring an additional 10,036 shares during the period. Capital Investment Advisory Services LLC acquired a new position in shares of BioXcel Therapeutics during the second quarter worth about $53,000. Charles Schwab Investment Management Inc. acquired a new position in BioXcel Therapeutics during the second quarter worth about $138,000. Bank of New York Mellon Corp acquired a new position in BioXcel Therapeutics during the second quarter worth about $198,000. Finally, Renaissance Technologies LLC grew its position in BioXcel Therapeutics by 59.8% during the second quarter. Renaissance Technologies LLC now owns 71,600 shares of the company’s stock worth $785,000 after buying an additional 26,800 shares during the period. Institutional investors and hedge funds own 20.44% of the company’s stock.
Shares of NASDAQ:BTAI traded up $0.03 on Friday, reaching $4.08. The company’s stock had a trading volume of 56,500 shares, compared to its average volume of 67,778. The stock’s 50-day moving average is $6.15 and its two-hundred day moving average is $9.32. BioXcel Therapeutics has a 52-week low of $2.41 and a 52-week high of $12.00. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.93 and a quick ratio of 3.93. The stock has a market capitalization of $67.96 million, a P/E ratio of -3.09 and a beta of 2.80.
About BioXcel Therapeutics
BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers.
Recommended Story: What are the benefits of buying treasury bonds?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.